Laura Olivié
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laura Olivié has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
José M. Serratosa
Hospital Universitario Fundación Jiménez Díaz Madrid Spain
2 shared publications- Víctor Soto-Insuga
Hospital Universitario Infantil Niño Jesús Madrid Spain
2 shared publications Alba Sierra-Marcos
MECBA (Instituto de Medicina y Cirugía de Barcelona), Barcelona, Spain
1 shared publicationAlba Sierra‐Marcos
Hospital Universitario Santa Creu i Sant Pau Institut de Recerca Sant Pau Barcelona Spain
1 shared publicationAlba Vieira Campos
Epilepsy Program, Neurology Department, Hospital Universitario La Princesa, Madrid, Spain
1 shared publicationAlberto Andrés López
Department of Neurology, IIS-Fundación Jiménez Díaz, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in SSRN Electronic Journal
Dissecting epileptic activity and neurological dysfunction in a preclinical B-Raf+/LSLV600E mouse model of cardio-facio-cutaneous syndrome
Cardio-facio-cutaneous (CFC) syndrome is a developmental disorder caused by germline mutations in components of the RAS/RAF/MEK/ERK signaling pathway. It is characterized by craniofacial dysmorphism, congenital heart defects, and intellectual disability. Most patients with CFC syndrome carry mutations in the BRAF locus that result in constitutive activation of the B-RAF kinase. A mouse model of this syndrome was generated by expressing limited amounts of the oncogenic B-RAFV600E protein from a germline B-RafLSLV600E allele. This strain recapitulates key features of CFC syndrome, including small body size, reduced survival, craniofacial abnormalities, cardiac hypertrophy, and epileptic seizures. In this study, we characterized the neurological dysfunction and epileptic activity of this experimental model. We show that B-Raf+/LSLV600E mice exhibit cerebral ventriculomegaly, hyperactivity, increased stereotyped movements, abnormal posturing, and cognitive deficits. Electroencephalographic evaluation revealed asymmetric background activity, interictal epileptiform discharges, and multiple seizure types, including generalized, focal, and focal-to-bilateral tonic-clonic seizures. By providing an expanded neuroanatomical characterization alongside the first quantitative behavioral, cognitive, and video-EEG analyses, these findings validate the B-Raf+/LSLV600E mouse for investigating the neurophysiological mechanisms underlying CFC syndrome and related developmental RASopathies. Ultimately, these outcomes establish the B-Raf+/LSLV600E model as a valuable platform for evaluating therapeutic strategies aimed at alleviating neurological symptoms.
- 21 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDissecting epileptic activity and neurological dysfunction in a preclinical B-Raf+/LSLV600E mouse model of cardio-facio-cutaneous syndrome
Cardio-facio-cutaneous (CFC) syndrome is a developmental disorder caused by germline mutations in components of the RAS/RAF/MEK/ERK signaling pathway. It is characterized by craniofacial dysmorphism, congenital heart defects, and intellectual disability. Most patients with CFC syndrome carry mutations in the BRAF locus that result in constitutive activation of the B-RAF kinase. A mouse model of this syndrome was generated by expressing limited amounts of the oncogenic B-RAFV600E protein from a germline B-RafLSLV600E allele. This strain recapitulates key features of CFC syndrome, including small body size, reduced survival, craniofacial abnormalities, cardiac hypertrophy, and epileptic seizures. In this study, we characterized the neurological dysfunction and epileptic activity of this experimental model. We show that B-Raf+/LSLV600E mice exhibit cerebral ventriculomegaly, hyperactivity, increased stereotyped movements, abnormal posturing, and cognitive deficits. Electroencephalographic evaluation revealed asymmetric background activity, interictal epileptiform discharges, and multiple seizure types, including generalized, focal, and focal-to-bilateral tonic-clonic seizures. By providing an expanded neuroanatomical characterization alongside the first quantitative behavioral, cognitive, and video-EEG analyses, these findings validate the B-Raf+/LSLV600E mouse for investigating the neurophysiological mechanisms underlying CFC syndrome and related developmental RASopathies. Ultimately, these outcomes establish the B-Raf+/LSLV600E model as a valuable platform for evaluating therapeutic strategies aimed at alleviating neurological symptoms.
- Open Access
Effectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study
Objective: Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs. Methods: In this multicenter, retrospective, real‐world study, FFA treatment was initiated ≥12 months before database closure. Data from patients' charts at 3, 6 and 12 months were recorded in the Spanish Epilepsy Society's DEEs registry. Effectiveness endpoints included seizure reductions of 100%, ≥75%, and ≥50% (responder), median percent seizure reduction, and seizure worsening. Safety endpoints included adverse event (AE) rates. Results: The study included 166 patients (LGS, n = 84; DS, n = 42; other DEE, n = 40; mean age 16.6 ± 12.1 years [111 pediatric, median 10.1 years; 55 adult, median 26.5 years]). Patients had a median of 3 prior failed anti‐seizure medications (ASMs). At 12 months, the median FFA dose was 0.49 mg/kg/day, with 77.1% treatment retention. There was a 68.8% median reduction in seizure frequency between baseline and 12 months ( p < .001), with significant reductions across all diagnostic groups (LGS, p < .001; DS, p < .001; other DEE, p = .004). The 12‐month ≥50% responder rate was 61%, with no statistically significant differences according to age. At 12 months, there were significant reductions in the mean number of concomitant ASMs ( p = .004) and the proportion of patients requiring rescue medication ( p < .001). Meaningful improvements in Clinical Global Impression scores for cognition (59.3% of patients), behavior (40.9%), sleep (24.3%), and caregiver (44.8%) domains were observed. At 12 months, AEs were reported in 68.1% of patients (mostly mild‐to‐moderate) and AEs leading to discontinuation in 12%, with no significant differences according to age. Significance: FFA was effective, with predictable tolerability, in patients with different DEEs and seizure types, supporting its use as an effective treatment option in pediatric and adult patients with DEEs.
Open AccessEffectiveness and tolerability of fenfluramine in pediatric and adult patients with developmental and epileptic encephalopathies: A multicenter, retrospective, real‐world clinical‐practice study
Objective: Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs. Methods: In this multicenter, retrospective, real‐world study, FFA treatment was initiated ≥12 months before database closure. Data from patients' charts at 3, 6 and 12 months were recorded in the Spanish Epilepsy Society's DEEs registry. Effectiveness endpoints included seizure reductions of 100%, ≥75%, and ≥50% (responder), median percent seizure reduction, and seizure worsening. Safety endpoints included adverse event (AE) rates. Results: The study included 166 patients (LGS, n = 84; DS, n = 42; other DEE, n = 40; mean age 16.6 ± 12.1 years [111 pediatric, median 10.1 years; 55 adult, median 26.5 years]). Patients had a median of 3 prior failed anti‐seizure medications (ASMs). At 12 months, the median FFA dose was 0.49 mg/kg/day, with 77.1% treatment retention. There was a 68.8% median reduction in seizure frequency between baseline and 12 months ( p < .001), with significant reductions across all diagnostic groups (LGS, p < .001; DS, p < .001; other DEE, p = .004). The 12‐month ≥50% responder rate was 61%, with no statistically significant differences according to age. At 12 months, there were significant reductions in the mean number of concomitant ASMs ( p = .004) and the proportion of patients requiring rescue medication ( p < .001). Meaningful improvements in Clinical Global Impression scores for cognition (59.3% of patients), behavior (40.9%), sleep (24.3%), and caregiver (44.8%) domains were observed. At 12 months, AEs were reported in 68.1% of patients (mostly mild‐to‐moderate) and AEs leading to discontinuation in 12%, with no significant differences according to age. Significance: FFA was effective, with predictable tolerability, in patients with different DEEs and seizure types, supporting its use as an effective treatment option in pediatric and adult patients with DEEs.
- 27 May 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 84-89
Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: A multicenter real-world study in Spain
- 27 May 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 84-89
Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: A multicenter real-world study in Spain
- 5 April 2024
- Published by BMJ in Practical Neurology
- Vol. 25 (1) , 87-92
Acute proximal weakness and paraesthesiae
While hospitalised and awaiting vertebroplasty, he developed mild confusion, vomiting and constipation, initially attributed to analgesics (opioids, dexketoprofen and metamizole). His symptoms progressed to oral intolerance with abdominal pain and distension, requiring a nasogastric tube. Given the clinical suspicion of an intestinal obstruction, an X-ray of abdomen showed dilation of intestinal loops. Blood tests identified severe hyponatraemia (serum sodium 123 mmol/L (137–144)) and elevated acute phase reactants including C reactive protein 9 mg/L (<0.05). CT scan of abdomen was compatible with an intestinal obstruction.
- 5 April 2024
- Published by BMJ in Practical Neurology
- Vol. 25 (1) , 87-92
Acute proximal weakness and paraesthesiae
While hospitalised and awaiting vertebroplasty, he developed mild confusion, vomiting and constipation, initially attributed to analgesics (opioids, dexketoprofen and metamizole). His symptoms progressed to oral intolerance with abdominal pain and distension, requiring a nasogastric tube. Given the clinical suspicion of an intestinal obstruction, an X-ray of abdomen showed dilation of intestinal loops. Blood tests identified severe hyponatraemia (serum sodium 123 mmol/L (137–144)) and elevated acute phase reactants including C reactive protein 9 mg/L (<0.05). CT scan of abdomen was compatible with an intestinal obstruction.
- 1 November 2019
- Published by Elsevier in Journal of Electrocardiology
- Vol. 57, 1-5
Advanced interatrial block: An electrocardiographic marker for stroke recurrence
- 1 November 2019
- Published by Elsevier in Journal of Electrocardiology
- Vol. 57, 1-5
Advanced interatrial block: An electrocardiographic marker for stroke recurrence
- 1 August 2019
- Published by Elsevier in Epilepsy Research
- Vol. 154, 39-41
Glut1 deficiency is a rare but treatable cause of childhood absence epilepsy with atypical features
- 1 August 2019
- Published by Elsevier in Epilepsy Research
- Vol. 154, 39-41
Glut1 deficiency is a rare but treatable cause of childhood absence epilepsy with atypical features
- 1 July 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 69, 218-220
External trigeminal nerve stimulation: A long term follow up study
- 1 July 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 69, 218-220
External trigeminal nerve stimulation: A long term follow up study
- 26 April 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 52 (1) , 25-31
Diversity of Cognitive Phenotypes Associated with C9ORF72 Hexanucleotide Expansion
For diagnostic purposes, we screened for the C9ORF72 mutation in a) 162 FTLD cases, and b) 145 cases with other diagnoses but with some frontotemporal features or manifestations previously reported in C9 carriers. Ten cases (onset 50 to 75 years) har
- 26 April 2016
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 52 (1) , 25-31
Diversity of Cognitive Phenotypes Associated with C9ORF72 Hexanucleotide Expansion
For diagnostic purposes, we screened for the C9ORF72 mutation in a) 162 FTLD cases, and b) 145 cases with other diagnoses but with some frontotemporal features or manifestations previously reported in C9 carriers. Ten cases (onset 50 to 75 years) har